Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PRX019 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PRX019, single dose | EXPERIMENTAL | Specified dose on specified days |
| PRX019, multiple dose | EXPERIMENTAL | Specified dose on specified days |
| Name | Type | Description |
|---|---|---|
| PRX019 | DRUG | Specified dose on specified days |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Male and female participants who are healthy as determined by the investigator based on review of medical history, physical examination, and clinical laboratory tests obtained during the screening period * Participant is willing and able to adhere to the study visit schedule a...
PRX019 is an investigational small molecule being developed by Prothena Corporation plc. It is currently in Phase 1 clinical development. A Phase 1 study of PRX019 in healthy adult volunteers has been completed, with 50 participants enrolled.
PRX019 is being studied in healthy participants as part of a Phase 1 clinical trial. The study is designed to evaluate the drug in healthy adult volunteers, and the specific therapeutic indication has not been established yet.
PRX019 is developed by Prothena Corporation plc, a biopharmaceutical company. Prothena is publicly traded on the Nasdaq under the ticker symbol PRTA.
PRX019 is in Phase 1 clinical development. A Phase 1 study of PRX019 in healthy adult volunteers has been completed, with 50 participants enrolled.
PRX019 has one completed Phase 1 clinical trial, identified as NCT06699680. This study, titled 'Phase 1 Study of PRX019 in Healthy Adult Volunteers,' enrolled 50 participants in the United States and was a randomized, double-blind, controlled trial.
PRX019 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. A Phase 1 study in healthy volunteers has been completed, but the drug has not yet been approved for any use.